PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB. (17th June 2021) - Shadman, M.; Sharman, J. P.; Levy, M. Y.; Porter, R.; Zafar, S. F.; Burke, J. M.; Chaudhry, A.; Freeman, B.; Misleh, J.; Yimer, H. A.; Cultrera, J. L.; Guthrie, T. H.; et al.